Fosun Pharma Plans $34M Nature's Sunshine Stock Sale, Company Plans $15M Buyback

Fosun Pharma USA is set to divest up to 2.85 million shares of Nature’s Sunshine Products (NATR) at a price of $12.00 per share in a secondary public offering expected to close by June 27, 2025. Nature’s Sunshine will not receive proceeds from the sale but may repurchase up to $15 million of the offered shares as part of its existing buyback program, potentially funding this with cash on hand and credit facility draws. The offering caused a sharp drop in Nature’s Sunshine shares, falling about 16% in premarket trading due to the discounted selling price compared to the previous closing price of $14.84. Analysts project a significant upside for NATR with an average price target of around $20, suggesting a potential gain of nearly 35%. The company maintains a strong balance sheet, with more cash than debt and a healthy current ratio, supporting its capacity to repurchase shares. Fosun Pharma will bear underwriting and transfer costs related to the resale, while Nature’s Sunshine will cover registration-related expenses, with D.A. Davidson & Co. acting as the sole book-running manager for the offering.